Drugs / EG-1962
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02790632 | Jul 2016 → Jun 2018 | acquired aneurysmal subarachnoid hemorrhage | Edge Therapeutics Inc | Terminated | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-1962 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02790632 ↗ |
| Known as | nimodipine | “EG-1962 is a sustained release formulation of nimodipine administered via external ventricular drain in patients with aneurysmal subarachnoid hemorrhage.” PMID 32138631 ↗ Mar 2020 |
| Route | Other | “administered intraventricularly” PMID 30014184 ↗ Feb 2019 |